Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print February 13, 2008, doi:10.1212/01.wnl.0000294325.63006.f8)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000294325.63006.f8v1
70/13_Part_2/1113    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Jager, P. L.
Right arrow Articles by Ascherio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Jager, P. L.
Right arrow Articles by Ascherio, A.
Received July 18, 2007
Accepted September 14, 2007

Integrating risk factors. HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis

P. L. De Jager MD, PhD, K. C. Simon DSc, K. L. Munger MSc, J. D. Rioux PhD, D. A. Hafler MD, and A. Ascherio MD, DrPH*

From the Center for Neurologic Diseases, Department of Neurology (P.L.D.J., D.A.H.), and Channing Laboratory, Department of Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Medical School/Partners Healthcare Center for Genetics and Genomics (P.L.D.J., D.A.H.); Broad Institute (P.L.D.J., J.D.R., D.A.H.), Massachusetts Institute of Technology and Harvard University, Cambridge; Departments of Epidemiology (K.C.S., A.A.) and Nutrition (K.L.M., A.A.), Harvard School of Public Health, Cambridge, MA; and University of Montreal (J.D.R.), Montreal Heart Institute, Montreal, Quebec, Canada.


* To whom correspondence should be addressed. E-mail: aascheri{at}hsph.harvard.edu.

ABSTRACT

Background: Individuals with high levels of antibodies to the Epstein–Barr virus nuclear antigen 1 (EBNA-1) have an increased risk of developing multiple sclerosis (MS), but this association could be confounded by genetic susceptibility.

Methods: We conducted a nested case-control study including 148 women with MS (18 with blood collected before disease onset) and 296 age-matched healthy women to determine whether the human leukocyte antigen (HLA) DRB1*1501 allele (DR15) and anti-Epstein–Barr virus (anti-EBV) antibody titers are independent risk factors for MS.

Results: The association between anti-EBNA-1 antibody titers and MS risk was not affected by adjustment for DR15 and was similar in DR15-positive and DR15-negative women. The relative risk of MS among DR15-positive women with elevated (>1:320) anti-EBNA-1 titers was ninefold higher than that of DR15-negative women with low (<1:80) anti-EBNA-1 titers.

Conclusions: Anti-Epstein–Barr virus nuclear antigen 1 (anti-EBNA-1) antibody titers are a risk factor for multiple sclerosis (MS), independently from the DR15 allele. Carriers of the DR15 allele with elevated anti-EBNA-1 antibody titers may have a markedly increased risk of MS.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. Bar-Or and J. Antel
Cross-reactivity between epidemiology and immunology in multiple sclerosis
Neurology, October 7, 2008; 71(15): 1132 - 1133.
[Full Text] [PDF]

Home page
 NeurologyHome page
R. A. Marrie
When one and one make three: HLA and EBV infection in MS
Neurology, March 25, 2008; 70(13_Part_2): 1067 - 1068.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.